ClinicalTrials.gg
RecruitingNCT06874842Updated Apr 1, 2025

Safety and Immunogenicity of the Recombinant Zoster Vaccine, LYB004 in Adults Aged 40 Years and Older

A Phase 1 interventional study of Low dose antigen and low dose adjuvant of LYB004 and Low dose antigen and high dose adjuvant of LYB004 in Herpes Zoster (HZ), sponsored by Guangzhou Patronus Biotech Co., Ltd.. Recruiting at 1 site in China. Open to participants aged 40 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-04-01.

Sponsored by Guangzhou Patronus Biotech Co., Ltd. · Phase 1, Interventional, and Prevention

From the registry’s dates

  • Primary completion was expected by Feb 2026, 9 months ago, but the record still lists the study as recruiting.
  • Started Mar 2025; still recruiting 1 year 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
92
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 51 studies in Herpes Zoster with a site in China — 26 open to participants now, 31 under way, 3 of them phase 3. Herpes Zoster · China.

Planned enrollment
35th of 45
92 · median 519
Started
2025
with 19 others
Phase 1
3 of 51
1 open now
Primary completion
2026-02
later than 6 of 30 live
Registered
28th of 51
by date
Lead sponsor
2 of 51
Guangzhou Patronus Biotech Co., Ltd.

Among the 51 studies in Herpes Zoster with a site in China, this one is the 35th largest by planned enrollment of the 45 interventional ones that give a count, is one of 20 that started in 2025, is one of 3 in phase 1, reaches primary completion later than 6 of the 30 other live ones, and was the 28th registered.

Herpes Zoster

299 studies on the registry are indexed under Herpes Zoster; 55 are open to participants now.

Browse Herpes Zoster studies →

Open to participants now

26 of the 51 studies in Herpes Zoster with a site in China are open now. Recruiting first, the newest first:

20 more — sign in →

All 26 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 37 Herpes Zoster studies recruiting now, 26 (70%) set no upper age limit and 6 (16%) stop at 75 or younger; 3 take children under 18; 13 take healthy volunteers.

This study: 40 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 51 studies in Herpes Zoster with a site in China, or all of them as a file.
02

Study summary

This phase 1 study in China will evaluate the safety and immunogenicity of the Recombinant Zoster Vaccine, LYB004 in adults aged 40 years and older.

Read the detailed description

A randomized, observer-blinded, positive-controlled, dose escalation trial will be conducted to observe the safety and immunogenicity of LYB004 in adults aged 40 years and older. A total of 92 healthy subjects will be enrolled and stratified by age (40-49,50-59 years and ≥60 years in a 5:6:8 ratio). Four formulations of LYB004 will be provided, two dose levels of antigen and two dose levels of adjuvant.

A sentinel and escalating dosing approach will be used for close monitoring of safety to minimize risk to participants. Participants will be enrolled in one of six cohorts, including Cohort 1 (40-49 years, low dose, n=10), Cohort 2 (50-59 years, low dose, n=12), Cohort 3 (≥60 years, low dose, n=24), Cohort 4 (40-49 years, high dose, n=10), Cohort 5 (50-59 years, high dose, n=12), and Cohort 6 (≥60 years, high dose, n=24). In Cohort 1 and Cohort 4, three sentinels each were set up, and they were randomly vaccinated with the investigational vaccine (low dose adjuvant), the investigational vaccine (high dose adjuvant), or a placebo in a 1:1:1 ratio. The remaining participants were randomly vaccinated in a 3:3:1 ratio with the low dose investigational vaccine (low dose adjuvant), the low dose investigational vaccine (high dose adjuvant), or a placebo. In Cohort 2 and Cohort 5, four sentinels each were set up, and they were randomly vaccinated with the investigational vaccine (low dose adjuvant), the investigational vaccine (high dose adjuvant), a positive control/Shingrix®, or a placebo in a 1:1:1:1 ratio. The remaining participants were randomly vaccinated in a 3:3:1:1 ratio with the same options. In Cohort 3 and Cohort 6, four sentinels each were also set up, and they were randomly vaccinated in a 1:1:1:1 ratio with the investigational vaccine (low dose adjuvant), the investigational vaccine (high dose adjuvant), a positive control/Shingrix®, or a placebo. The remaining participants were randomly vaccinated in a 7:7:3:3 ratio with the same options. The two-dose immunization schedule will be adopted, that is, LYB004 or Shingrix® or placebo will be intramuscularly injected on Day 0 and Day 60, respectively.

03

Conditions studied

  • Herpes Zoster (HZ)

Keywords

  • herpes zoster
  • shingles
  • varicella zoster virus
  • Virus-Like Particles
  • vaccine
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Residents aged 40 years and older (at the time of screening), regardless of gender;
  2. Participants can provide valid identification, voluntarily agree to participate in the study, and sign the Form;
  3. Participants are able to attend all planned follow-up visits and comply with the protocol requirements;
  4. Females of should use effective measures one month before enrollment; females of childbearing potential (excluding those who have undergone tubal ligation, bilateral oophorectomy, or hysterectomy) and male participants should practice effective contraception and avoid pregnancy plans, as well as sperm or egg donation plans from the time of enrollment until 6 months after the full course of vaccination. Effective contraceptive methods include oral contraceptives (excluding emergency contraceptives), injectable or implantable contraceptives, sustained-release local contraceptives, contraceptive patches, intrauterine devices, sterilization, abstinence, condoms, diaphragms, cervical caps, etc.

Exclusion criteria

Exclusion Criteria:

  1. Axillary temperature ≥ 37.3°C;
  2. History of herpes zoster before vaccination with the vaccine;
  3. Previous vaccination against HZ or varicella;
  4. Has had close contact with patients with varicella/herpes zoster within 6 months before vaccination with the investigational vaccine;
  5. Has received any vaccine within 14 days before vaccination, or have received a within 28 days;
  6. Have been injected with gamma globulin or intravenous immunoglobulin within 3 months before vaccination;
  7. Individual with the following diseases: ① Have acute diseases or are in the acute exacerbation period of chronic diseases, or take antipyretic, analgesic, and anti-allergic drugs within 3 days before vaccination; ② Allergies to any component of the study vaccine, or have a history of severe allergic reactions to any vaccination; ③ History of convulsions, epilepsy, encephalopathy (such as congenital brain dysplasia, brain trauma, brain tumors, cerebral hemorrhage, cerebral infarction, brain infection, chemical poisoning, etc. causing brain nerve tissue damage, etc.) and mental illness, or a family history of mental illness; ④ Asplenia, or functional asplenia; ⑤Primary or secondary immunodeficiency, or diagnosed with congenital or acquired immunodeficiency, infection, lymphoma, leukemia, systemic lupus erythematosus, rheumatoid arthritis, juvenile rheumatoid arthritis, inflammatory bowel disease, or other diseases; ⑥ Chronic administration (≥14 consecutive days) of (reference value for dose: ≥ 2mg/kg/day or ≥ 20mg/day prednisone or equivalent) or other agents within the past 3 months, with the exception of inhaled or topical steroids, or short-term use (\<14 consecutive days) of oral corticosteroids; ⑦ Severe cardiovascular diseases (pulmonary heart disease, pulmonary edema, etc.), severe liver and kidney diseases, complicated diabetes; ⑧ History of thrombocytopenia or other coagulation disorders that may contraindicate intramuscular injection;⑨Severe hypertension that cannot be controlled by medication (on-site measurement: systolic blood pressure ≥ 140mmHg and/or diastolic blood pressure ≥ 90mmHg);
  8. Abnormal laboratory test indicators specified in the protocol before vaccination and determined by the clinical investigator to be of clinical significance;
  9. History of long-term alcohol abuse and/or drug abuse;
  10. Individual who is currently participating in other research or unregistered product (drugs, vaccines, or devices, etc.) clinical studies, or plan to participate in other clinical studies before the end of this clinical study;
  11. Exclusion criteria for specific populations: lactating or pregnant women during the clinical research period, or women of childbearing age with a positive pregnancy test before vaccination;
  12. Other conditions that may impact the subject's safety or influence the assessment of vaccine response, as determined by the investigator.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 1
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
92 participants (estimated)

Study arms

  • Experimental
    Low dose antigen and low dose adjuvant of LYB004

    Subjects aged 40 years and older will be vaccinated with 2 doses of LYB004 (low dose antigen and low dose adjuvant) on a 0, 2 month schedule, administered intramuscularly (IM).

    Biological: Low dose antigen and low dose adjuvant of LYB004

  • Experimental
    Low dose antigen and high dose adjuvant of LYB004

    Subjects aged 40 years and older will be vaccinated with 2 doses of LYB004 (low dose antigen and high dose adjuvant ) on a 0, 2 month schedule, administered intramuscularly (IM).

    Biological: Low dose antigen and high dose adjuvant of LYB004

  • Placebo comparator
    Placebo

    Subjects aged 40 years and older will be vaccinated with 2 doses of placebo on a 0, 2 month schedule, administered intramuscularly (IM).

    Biological: Placebo

  • Active comparator
    Positive control

    Subjects aged 50 years and older will be vaccinated with 2 doses of Shingrix® on a 0, 2 month schedule, administered intramuscularly (IM).

    Biological: Positive control

  • Experimental
    High dose antigen and low dose adjuvant of LYB004

    Subjects aged 40 years and older will be vaccinated with 2 doses of LYB004 (high dose antigen and low dose adjuvant) on a 0, 2 month schedule, administered intramuscularly (IM).

    Biological: High dose antigen and low dose adjuvant of LYB004

  • Experimental
    High dose antigen and high dose adjuvant of LYB004

    Subjects aged 40 years and older will be vaccinated with 2 doses of LYB004 (high dose antigen and high dose adjuvant) on a 0, 2 month schedule, administered intramuscularly (IM).

    Biological: High dose antigen and high dose adjuvant of LYB004

Interventions

  • BiologicalLow dose antigen and low dose adjuvant of LYB004

    0.5 mL per dose, containing a total of 25 μg VZV-gEM adjuvanted with A01C.

  • BiologicalLow dose antigen and high dose adjuvant of LYB004

    0.5 mL per dose, containing a total of 25 μg VZV-gEM adjuvanted with A01B.

  • BiologicalHigh dose antigen and low dose adjuvant of LYB004

    0.5 mL per dose, containing a total of 50 μg VZV-gEM adjuvanted with A01C.

  • BiologicalHigh dose antigen and high dose adjuvant of LYB004

    0.5 mL per dose, containing a total of 50 μg VZV-gEM adjuvanted with A01B.

  • BiologicalPlacebo

    0.5 mL per dose, without antigen and adjuvant.

  • 0.5 mL per dose, containing a total of 50 µg recombinant varicella zoster virus glycoprotein E, adjuvanted with AS01B.

    Also known as: Shingrix®

06

What researchers measure

Primary outcomes

  1. Occurrence of immediate adverse events

    The incidence and severity of any adverse events (AEs) within 30 minutes after each vaccination

    Time frame: Within 30 minutes after each vaccination

  2. Incidence of solicited AE

    Occurrence and severity of solicited local injection site reactions for 14 days (Day 0-Day 14) following each vaccination. (i.e., pain, redness, swelling). Occurrence and severity of solicited systemic reactions for 14 days (Day 0-Day 14) following each vaccination. (i.e., myalgia, fatigue, headache, chills, fever).

    Time frame: Within 0-14 days after each vaccination

  3. Incidence of unsolicited AEs

    The incidence and severity of any unsolicited AEs, including all AEs, except solicited AEs reported Days 0\~30 after the study intervention. vaccination

    Time frame: Within 30 days after each vaccination

  4. Incidence of clinically significant abnormalities in clinical laboratory tests

    The incidence of clinically significant abnormalities in clinical laboratory tests (hematology, blood chemistry, coagulation function, and urinalysis) on Day 3 after each vaccination

    Time frame: 3 days after each vaccination

Secondary outcomes

  1. Occurrence of serious adverse events (SAEs) and adverse events of special interests (AESIs)

    The incidence of any serious adverse events (SAEs) and adverse events of special interest (AESIs) from the first vaccination up to 12 months after the second vaccination

    Time frame: From the first vaccination up to 12 months after the second vaccination

  2. The seroconversion rate of anti-Varicella Zoster Virus (VZV) antibody

    Seroconversion refers to at least a 4-fold increase in the anti-Varicella Zoster Virus (VZV) antibody titer at the endpoint as compared to the prevaccination titer if prevaccination titer is above the lower limit of quantification (LLOQ) or a 4-fold increase at the endpoint as compared to LLOQ value if prevaccination concentration is lower than LLOQ.

    Time frame: 30 days and 60 days after first vaccination, 14 days, 30 days, 6 months and 12 months after second vaccination

  3. The seroconversion rate of anti-glycoprotein E (gE) antibody

    Seroconversion refers to at least a 4-fold increase in the anti-glycoprotein E (gE) antibody concentration at the endpoint as compared to the prevaccination concentration if prevaccination concentration is above the lower limit of quantification (LLOQ) or a 4-fold increase at the endpoint as compared to LLOQ value if prevaccination concentration is lower than LLOQ.

    Time frame: 30 days and 60 days after first vaccination, 14 days, 30 days, 6 months and 12 months after second vaccination

  4. The geometric mean titer (GMT) of anti-VZV antibody

    Measured by fluorescent antibody to the membrane antigen (FAMA).

    Time frame: 30 days and 60 days after first vaccination, 14 days, 30 days, 6 months and 12 months after second vaccination

  5. The geometric mean concentration (GMC) of anti-glycoprotein E (gE) antibody

    Measured by Enzyme-Linked Immunosorbent Assay (ELISA).

    Time frame: 30 days and 60 days after first vaccination, 14 days, 30 days, 6 months and 12 months after second vaccination

  6. The geometric mean fold rise (GMFR) of anti-VZV antibody

    Change from prevaccination in geometric mean fold rise of anti-VZV antibody titer.

    Time frame: 30 days and 60 days after first vaccination, 14 days, 30 days, 6 months and 12 months after second vaccination

  7. The GMFR of anti-gE antibody

    Change from prevaccination in geometric mean fold rise of anti-gE antibody concentration.

    Time frame: 30 days and 60 days after first vaccination, 14 days, 30 days, 6 months and 12 months after second vaccination

  8. Frequencies of CD4+ T cells secreting at least two of gE specific activation markers (IFN-γ, IL-2, TNF-α, CD40L) per 10^6 CD4+ T cells, and the cell mediated immunity (CMI) response rates at timepoints during the study

    The frequencies of CD4+ T cells secreting at least two of gE specific activation markers (IFN-γ, IL-2, TNF-α, CD40L) per 106 CD4+ T cells, and the cell mediated immunity (CMI) response rates at 30 days after first vaccination, 30 days and 6 months after second vaccination.

    Time frame: 30 days after first vaccination, 30 days and 6 months after second vaccination

  9. Frequencies of CD8+ T cells secreting at least two of gE specific activation markers (IFN-γ, IL-2, TNF-α, CD40L) per 10^6 CD8+ T cells, and the cell mediated immunity (CMI) response rates at timepoints during the study

    The frequencies of CD8+ T cells secreting at least two of gE specific activation markers (IFN-γ, IL-2, TNF-α, CD40L) per 10\^6 CD8+ T cells, and the cell mediated immunity (CMI) response rates at 30 days after first vaccination, 30 days and 6 months after second vaccination.

    Time frame: 30 days after first vaccination, 30 days and 6 months after second vaccination

07

Study locations

1 of 1 sites recruiting
  • Guangdong Provincial Center for Disease Control and Prevention
    Meizhou, China
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2025 (actual). Primary completion is estimated for Feb 2026, 11 months after the start.

Of 21 phase 1 interventional studies under Herpes Zoster, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 22. This study's planned 11 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 3, 2025
First posted
Mar 13, 2025
StartActual
Mar 13, 2025
Primary completionEst.
Feb 2026
CompletionEst.
Oct 2026
Last update
Apr 1, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 1, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06874842
Lead sponsor
Guangzhou Patronus Biotech Co., Ltd.
Responsible party
Sponsor
First posted
Mar 13, 2025
Start date
Mar 13, 2025
Primary completion
Feb 2026 (estimated)
Completion
Oct 2026 (estimated)
Last update
Apr 1, 2025

Study contacts

Renfeng Fan
Contact
gdsjkzx_sws_sps@gd.gov.cn
8613560231815
Renfeng Fan
principal investigator · Guangdong Center for Disease Prevention and Control

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion